查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1611097

苯酮尿症治疗市场规模、份额、趋势分析报告：按药物、剂型、地区和细分市场预测，2025-2030年

Phenylketonuria Treatment Market Size, Share & Trends Analysis Report By Drug (Kuvan, Palynziq), By Mode of Administration (Oral Administration, Parenteral Administration), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

苯酮尿症 (PKU) 治疗市场成长和趋势

Grand View Research, Inc.最新报告显示，到2030年，全球苯酮尿症治疗市场规模预计将达到8.51亿美元，2025年至2030年复合年增长率为9.4%。全球 PKU 盛行率不断上升，有利的政府法规预计将在预测期内推动市场成长。

例如，根据 FDA 的数据，2018 年美国大约每 10,000 至 15,000 人中就有 1 人患有苯酮尿症。此外，根据 Orphanet 报告，估计欧洲每 10,000 名新生儿中就有 1 人受到 PKU 的影响。此病在义大利、爱尔兰、土耳其等欧洲国家发病率较高。据估计，土耳其每 4,000 人中约有 1 人被诊断出患有 PKU。

私人和公共组织开展的各种意识计划预计也将推动市场成长。进行此类计画的组织包括 SickKids、威斯康辛州儿童医院、CHOC 儿童医院和波士顿儿童医院。这些计划旨在让 PKU 患者保持最佳的心理、发展和身体健康。

此外，疾病治疗的持续研究和开发预计将推动市场成长。例如，Synlogic, Inc.的SYNB1618正在进行1/2a期临床试验，也获得了FDA的简审类。此外，Rubius Therapeutics, Inc.、Retropin, Inc. 和 Homology Medicines, Inc. 等其他公司正在进行研究开发新疗法，包括口服疗法、酵素疗法和基因疗法。

预计 PKU 高成本治疗的报销措施也将促进市场成长。 Kuban 目前在许多欧洲国家核准使用和报销，包括德国、比利时、法国、义大利和奥地利。此外，预计各组织增加的研究和开发资助计划将推动市场的发展。例如，全国 PKU 联盟资助研究计划，帮助推进 PKU 管理和治疗的进步。

苯酮尿症治疗市场报告亮点

  • Palynziq 将在 2024 年占据最大份额，达到 67.9%，预计在预测期内将以显着的复合年增长率增长。
  • 由于成熟的医疗基础设施、高昂的医疗成本和有利的政府法规，2024 年苯酮尿症治疗市场将由北美主导。
  • 由于 PKU开发新药的研发活动活性化，预计欧洲在预测期内将呈现最快的复合年增长率。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章苯酮尿症治疗市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 营商环境分析
    • 产业分析-波特五力分析
    • PESTLE分析

第四章苯酮尿症治疗市场：医药业务分析

  • 2024年及2030年药品市场占有率
  • 医药细分仪表板
  • 2018-2030 年按药物分類的市场规模、预测与趋势分析
  • 库万
  • 帕林吉库
  • 其他的

第五章苯酮尿症治疗市场：剂量方法业务分析

  • 2024年及2030年剂量方法市场占有率
  • 计量方法细分仪表板
  • 2018-2030 年市场规模、预测与趋势分析（按管理方式）
  • 口服给药
  • 肠外给药

第六章 苯酮尿症治疗市场：按药物和给药方法分類的区域估计和趋势分析

  • 2024 年及 2030 年按地区分類的市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模、预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 参与者概览
  • 公司市场分析
  • 公司分类
  • 策略规划
  • 公司简介/上市公司
    • BioMarin
    • Synlogic
    • Travere Therapeutics, Inc.
    • DAIICHI SANKYO COMPANY, LIMITED.
    • Codexis, Inc.
    • SOM BIOTECH
    • Homology Medicines, Inc.（Q32 Bio Inc.）
Product Code: GVR-3-68038-310-2

Phenylketonuria Treatment Market Growth & Trends:

The global phenylketonuria treatment market size is expected to reach USD 851.0 million by 2030, registering a CAGR of 9.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of PKU across the world and favorable government regulations are the factors expected to spur the market growth over the forecast period.

For instance, according to the FDA, in 2018, phenylketonuria affected about 1 in 10,000 to 15,000 people in U.S. Furthermore, according to the Orphanet, it was estimated that 1 in 10,000 newborns in Europe is suffering from PKU. The target disease is highly prevalent in European countries, such as Italy, Ireland, and Turkey. It was estimated that around 1 in 4000 individuals in Turkey were diagnosed with PKU.

Various awareness programs conducted by private and public organizations are also projected to fuel market growth. Some of the organizations conducting such programs are SickKids, Children's Hospital of Wisconsin, CHOC Children's, and Boston Children's Hospital. These programs aim to promote optimal emotional, developmental, and physical health PKU patients.

Furthermore, continuous R&D for the disease treatment is estimated to enhance the market growth. For instance, Synlogic, Inc.'s SYNB1618 drug is undergoing Phase 1/2a clinical trials and also received fast-track designation from FDA. In addition, other companies, such as Rubius Therapeutics, Inc., Retrophin, Inc., and Homology Medicines, Inc. are also conducting research to develop novel therapies, such as oral, enzyme therapy, gene therapy.

Availability of reimbursement policies for high-cost treatments of PKU is also projected to boost the market growth. Kuvan is currently approved for use and reimbursed in many European countries, such as Germany, Belgium, France, Italy, and Austria. Furthermore, increasing number of funding programs for R&D by various organizations is anticipated to drive the market. For instance, the National PKU Alliance provides funding to research projects that helps in promoting advances in the management and treatment of PKU.

Phenylketonuria Treatment Market Report Highlights:

  • Palynziq accounted for the largest share of 67.9% in 2024 and is also expected to grow at a significant CAGR over the forecast period.
  • North America dominated the phenylketonuria treatment market in 2024 owing to the presence of well-established healthcare infrastructure, high healthcare expenditure, and favorable government regulations
  • Europe region is expected to exhibit the fastest CAGR over the forecast period owing to rising R&D activities for the development of new PKU drugs

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug
    • 1.2.2. Mode of Administration
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Phenylketonuria Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Phenylketonuria Treatment Market: Drug Business Analysis

  • 4.1. Drug Market Share, 2024 & 2030
  • 4.2. Drug Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug, 2018 to 2030 (USD Million)
  • 4.4. Kuvan
    • 4.4.1. Kuvan market, 2018 - 2030 (USD Million)
  • 4.5. Palynziq
    • 4.5.1. Palynziq market, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others market, 2018 - 2030 (USD Million)

Chapter 5. Phenylketonuria Treatment Market: Mode of Administration Business Analysis

  • 5.1. Mode of Administration Market Share, 2024 & 2030
  • 5.2. Mode of Administration Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Mode of Administration, 2018 to 2030 (USD Million)
  • 5.4. Oral Administration
    • 5.4.1. Oral administration market, 2018 - 2030 (USD Million)
  • 5.5. Parenteral Administration
    • 5.5.1. Parenteral administration market, 2018 - 2030 (USD Million)

Chapter 6. Phenylketonuria Treatment Market: Regional Estimates & Trend Analysis by Drug and Mode of Administration

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework
      • 6.4.2.3. Competitive insights
      • 6.4.2.4. U.S. phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework
      • 6.4.3.3. Competitive insights
      • 6.4.3.4. Canada phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework
      • 6.4.4.3. Competitive insights
      • 6.4.4.4. Mexico phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework
      • 6.5.2.3. Competitive insights
      • 6.5.2.4. UK phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework
      • 6.5.3.3. Competitive insights
      • 6.5.3.4. Germany phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework
      • 6.5.4.3. Competitive insights
      • 6.5.4.4. France phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework
      • 6.5.5.3. Competitive insights
      • 6.5.5.4. Italy phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework
      • 6.5.6.3. Competitive insights
      • 6.5.6.4. Spain phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key country dynamics
      • 6.5.7.2. Regulatory framework
      • 6.5.7.3. Competitive insights
      • 6.5.7.4. Denmark phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key country dynamics
      • 6.5.8.2. Regulatory framework
      • 6.5.8.3. Competitive insights
      • 6.5.8.4. Sweden phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key country dynamics
      • 6.5.9.2. Regulatory framework
      • 6.5.9.3. Competitive insights
      • 6.5.9.4. Norway phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework
      • 6.6.2.3. Competitive insights
      • 6.6.2.4. Japan phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework
      • 6.6.3.3. Competitive insights
      • 6.6.3.4. China phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework
      • 6.6.4.3. Competitive insights
      • 6.6.4.4. India phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework
      • 6.6.5.3. Competitive insights
      • 6.6.5.4. Australia phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework
      • 6.6.6.3. Competitive insights
      • 6.6.6.4. South Korea phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework
      • 6.6.7.3. Competitive insights
      • 6.6.7.4. Thailand phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework
      • 6.7.2.3. Competitive insights
      • 6.7.2.4. Brazil phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework
      • 6.7.3.3. Competitive insights
      • 6.7.3.4. Argentina phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework
      • 6.8.2.3. Competitive insights
      • 6.8.2.4. South Africa phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework
      • 6.8.3.3. Competitive insights
      • 6.8.3.4. Saudi Arabia phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key country dynamics
      • 6.8.4.2. Regulatory framework
      • 6.8.4.3. Competitive insights
      • 6.8.4.4. UAE phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key country dynamics
      • 6.8.5.2. Regulatory framework
      • 6.8.5.3. Competitive insights
      • 6.8.5.4. Kuwait phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. BioMarin
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial performance
      • 7.5.1.3. Product benchmarking
      • 7.5.1.4. Strategic initiatives
    • 7.5.2. Synlogic
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial performance
      • 7.5.2.3. Product benchmarking
      • 7.5.2.4. Strategic initiatives
    • 7.5.3. Travere Therapeutics, Inc.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial performance
      • 7.5.3.3. Product benchmarking
      • 7.5.3.4. Strategic initiatives
    • 7.5.4. DAIICHI SANKYO COMPANY, LIMITED.
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial performance
      • 7.5.4.3. Product benchmarking
      • 7.5.4.4. Strategic initiatives
    • 7.5.5. Codexis, Inc.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial performance
      • 7.5.5.3. Product benchmarking
      • 7.5.5.4. Strategic initiatives
    • 7.5.6. SOM BIOTECH
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial performance
      • 7.5.6.3. Product benchmarking
      • 7.5.6.4. Strategic initiatives
    • 7.5.7. Homology Medicines, Inc. (Q32 Bio Inc.)
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial performance
      • 7.5.7.3. Product benchmarking
      • 7.5.7.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global phenylketonuria treatment market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 5 Global phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 6 North America Phenylketonuria treatment market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 8 North America phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 9 U.S. phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 10 U.S. phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 11 Canada phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 12 Canada phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 13 Mexico phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 14 Mexico phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 15 Europe phenylketonuria treatment market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 17 Europe phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 18 UK phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 19 UK phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 20 Germany phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 21 Germany phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 22 France phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 23 France phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 24 Italy phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 25 Italy phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 26 Spain phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 27 Spain phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 28 Denmark phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 29 Denmark phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 30 Sweden phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 31 Sweden phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 32 Norway phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 33 Norway phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific phenylketonuria treatment market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 37 Japan phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 38 Japan phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 39 China phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 40 China phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 41 India phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 42 India phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 43 Australia phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 44 Australia phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 45 South Korea phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 46 South Korea phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 47 Thailand phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 48 Thailand phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 49 Latin America phenylketonuria treatment market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 51 Latin America phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 52 Brazil phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 53 Brazil phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 54 Argentina phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 55 Argentina phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Phenylketonuria treatment market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 59 South Africa phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 60 South Africa phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 63 UAE phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 64 UAE phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 65 Kuwait phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 66 Kuwait phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Phenylketonuria treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Drug outlook (USD Million)
  • Fig. 10 Mode of administration outlook
  • Fig. 11 Competitive landscape
  • Fig. 12 Phenylketonuria treatment market dynamics
  • Fig. 13 Phenylketonuria treatment market: Porter's five forces analysis
  • Fig. 14 Phenylketonuria treatment market: PESTLE analysis
  • Fig. 15 Phenylketonuria treatment market: Drug segment dashboard
  • Fig. 16 Phenylketonuria treatment market: Drug market share analysis, 2024 & 2030
  • Fig. 17 Kuvan market, 2018 - 2030 (USD Million)
  • Fig. 18 Palynziq market, 2018 - 2030 (USD Million)
  • Fig. 19 Others market, 2018 - 2030 (USD Million)
  • Fig. 20 Phenylketonuria treatment market: Mode of administration segment dashboard
  • Fig. 21 Phenylketonuria treatment market: Mode of administration market share analysis, 2024 & 2030
  • Fig. 22 Oral administration market, 2018 - 2030 (USD Million)
  • Fig. 23 Parenteral administration market, 2018 - 2030 (USD Million)
  • Fig. 24 Phenylketonuria treatment market revenue, by region
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 North America phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. country dynamics
  • Fig. 29 U.S. phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 30 Canada country dynamics
  • Fig. 31 Canada phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 32 Mexico country dynamics
  • Fig. 33 Mexico phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 34 Europe phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 UK country dynamics
  • Fig. 36 UK phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany country dynamics
  • Fig. 38 Germany phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 39 France country dynamics
  • Fig. 40 France phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 Italy country dynamics
  • Fig. 42 Italy phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain country dynamics
  • Fig. 44 Spain phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark country dynamics
  • Fig. 46 Denmark phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 47 Sweden country dynamics
  • Fig. 48 Sweden phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 49 Norway country dynamics
  • Fig. 50 Norway phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Japan country dynamics
  • Fig. 53 Japan phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 China country dynamics
  • Fig. 55 China phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 India country dynamics
  • Fig. 57 India phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 58 Australia country dynamics
  • Fig. 59 Australia phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 60 South Korea country dynamics
  • Fig. 61 South Korea phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 62 Thailand country dynamics
  • Fig. 63 Thailand phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 64 Latin America phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 65 Brazil country dynamics
  • Fig. 66 Brazil phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 67 Argentina country dynamics
  • Fig. 68 Argentina phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 69 MEA phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 70 South Africa country dynamics
  • Fig. 71 South Africa phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 72 Saudi Arabia country dynamics
  • Fig. 73 Saudi Arabia phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 74 UAE country dynamics
  • Fig. 75 UAE phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 76 Kuwait Key country dynamics
  • Fig. 77 Kuwait phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 78 Company categorization
  • Fig. 79 Company market position analysis
  • Fig. 80 Strategic framework